KRAS and colorectal carcinoma: Meanwhile, it has also been demonstrated that (17) In CRC patients with KRAS mutations, pelareorep enhances immune efficacy and exerts tumor lytic effects by up-regulating the expression of surface peptides of MHC I molecules and activating CD4 and CD8 T cell populations.